Subcutaneous Drug Development & Delivery Consortium Inc
| Fiscal year | Revenue | Expenses | Net | Reserve mo. | Staff % |
|---|---|---|---|---|---|
| 2020 | 500,000 | 53,145 | 446,855 | 100.9 | 0% |
| 2021 | 600,000 | 280,411 | 319,589 | 32.8 | 0% |
| 2022 | 406,250 | 537,991 | −131,741 | 14.2 | 0% |
| 2023 | 760,000 | 769,199 | −9,199 | 9.8 | 0% |
In its most recent public year (2023), this organization spent $9,199 more than it brought in. Its reserves stood at about 9.8 months of spending, down from 100.9 in 2020. Staff pay was 0% of spending.
Reserve months = net assets ÷ average monthly spending; net assets count everything the organization owns beyond its debts — buildings and donor-restricted funds included, not just cash. Staff pay = salaries, wages, and officer compensation; it excludes benefits and payroll taxes. The IRS releases this data years after the fact — this organization's newest public year is 2023. Years refer to the calendar year in which the organization's fiscal year ended. Short-form filers do not publicly report donor-restricted balances or staffing costs. Source filings
Subcutaneous Drug Development & Delivery Consortium Inc's IRS filings as a feed — one entry per filing year, through 2023. Add the address to any feed reader; in Slack, send /feed subscribe with it (pasting the link alone won't subscribe). How this feed works